Capricor Therapeutics, Inc.
CAPR
$26.01
-$0.15-0.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 18.35% | 13.62% | |||
| Gross Profit | -18.35% | -13.62% | |||
| SG&A Expenses | 55.99% | 1.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.12% | 10.93% | |||
| Operating Income | -26.12% | -10.93% | |||
| Income Before Tax | -12.50% | -22.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.50% | -22.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.50% | -22.79% | |||
| EBIT | -26.12% | -10.93% | |||
| EBITDA | -26.47% | -11.11% | |||
| EPS Basic | 4.31% | -14.90% | |||
| Normalized Basic EPS | 4.53% | -14.95% | |||
| EPS Diluted | 4.31% | -14.90% | |||
| Normalized Diluted EPS | 4.53% | -14.95% | |||
| Average Basic Shares Outstanding | 17.57% | 6.86% | |||
| Average Diluted Shares Outstanding | 17.57% | 6.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||